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Obesity and hypertension, major risk factors for the metabolic syndrome, render individuals susceptible to an increased risk
of cardiovascular complications, such as adverse cardiac remodeling and heart failure. There has been much investigation into
the role that an increase in the renin-angiotensin-aldosterone system (RAAS) plays in the pathogenesis of metabolic syndrome
and in particular, how aldosterone mediates left ventricular hypertrophy and increased cardiac ﬁbrosis via its interaction with
the mineralocorticoid receptor (MR). Here, we review the pertinent ﬁndings that link obesity with elevated aldosterone and the
developmentofcardiachypertrophy andﬁbrosisassociatedwiththe metabolicsyndrome.These studies illustrate acomplex cross-
talk between adipose tissue, the heart, and the adrenal cortex. Furthermore, we discuss ﬁndings from our laboratory that suggest
thatcardiac hypertrophy andﬁbrosis inthe metabolic syndromemayinvolvecross-talk between aldosteroneandadipokines (such
as adiponectin).
1.Introduction
The metabolic syndrome is characterized by a collection of
cardiovascular risk factors that includeobesity, dyslipidemia,
hypertension, and glucose intolerance/insulin resistance and
together predispose individuals to an increased risk of heart
disease, stroke and diabetes [1, 2]. The increased prevalence
of obesity and the metabolic syndrome portends a greater
risk of cardiovascular disease such as heart failure and
premature death [3–6]. Nearly 70 million adults in the USA
are obese (deﬁned as a body mass index (BMI) ≥30kg/m2)
[7, 8]. Although the pathogenesis of the metabolic syndrome
has yet to be fully elucidated, increasing evidence has linked
the renin-angiotensin-aldosterone system (RAAS) with the
associated risk factors, including obesity and hypertension
[9–11]. Elevated plasma aldosterone levels are found in
patients with the metabolic syndrome [12], in resistant
hypertension [13, 14], and are associated with the devel-
opment of left ventricular (LV) hypertrophy (LVH) and
increased cardiac ﬁbrosis [13, 15, 16]. In addition, elevated
RAAS activity is evident in patients with congestive heart
failure[17].Importantly,patientswithobesity,hypertension,
or diabetes mellitus are prone to diastolic heart failure
which may be characterized by LVH. Proﬁbrotic and proin-
ﬂammatory eﬀects observed in heart failure patients have
been attributed to elevated angiotensin II (Ang-II) levels
[18, 19]; however, it is now believed that an elevation in
plasma aldosterone may also be in part responsible for these
events [17]. This paper focuses on the link between obesity,
aldosterone, and cardiac remodeling associated with the
metabolic syndrome.
2.AldosteroneProduction
Aldosteroneisprimarily synthesized in thezona glomerulosa
of the adrenal cortex and requires the coordinated activity
of several enzymes including that of aldosterone synthase
(CYP11B2), which mediates deoxycorticosterone catalysis
into aldosterone [20]. Angiotensin remains a primary stim-
ulus for aldosterone secretion in response to blood volume2 International Journal of Hypertension
depletion [21], but the production of aldosterone is also
increased in response to adrenocorticotropin, potassium
(K+), and other lipid soluble factors [9]. Normally, aldos-
terone can be extracted from the circulation and concen-
trated in the heart in both normal patients and those with
chronic heart failure [22, 23]. Although controversial, there
is conﬂicting evidence as to whether aldosterone may be
synthesized in the heart under certain pathologic conditions
and may be related to species, strain, and pathological
conditions.
For example, rats subjected to myocardial infarction
showed an increase in both cardiac aldosterone synthase
(CYP11B2) and aldosterone levels [24], whereas aldosterone
synthase mRNA was not found in Sprague Dawley rat hearts
unless the rats were subjected to chronic Ang-II infusions
[25]. Others have found an all together complete lack of
aldosterone synthase expression in rats [26]. Aldosterone
synthase expression has also been found to be elevated in
humans with heart failure [27], and aldosterone levels in
the coronary sinus were reported to be signiﬁcantly lower
than in the aortic root, in humans with congestive heart
failure and dilated cardiomyopathy, suggesting that plasma
aldosterone was extracted through the heart in these patients
[28]. However, it should be noted that mRNA levels of
aldosterone synthase are about 100 to 10,000 times lower
in the human heart than in the human adrenal gland [29].
Similarly, others have reported only aldosterone synthase
mRNA expression in the fetal heart [30]. Thus, the healthy
adult human heart does not appear to express aldosterone
synthase mRNA, whereas human fetal and failing adult
hearts do [29].
2.1. Adipose Tissue Can Regulate Aldosterone Secretion. In
addition to its role as a primary energy source, adipose
tissue serves as a highly active endocrine organ, capable
of secreting various factors (i.e., leptin, IL-6, TNF-α,a n d
adiponectin) into the circulation. These factors can aﬀect
adrenal functions by inﬂuencing steroidogenesis [31, 32],
which may ultimately aﬀect the cardiovascular system [33].
There has been a reported association between obesity
and hypertension via stimulation of aldosterone production
and the subsequent renal sodium retention [34]. Likewise,
adipocytes can mediate adrenal secretion of aldosterone
via the release of the so-called “aldosterone-stimulating
factors” [11, 13]. These secreted factors from visceral or
subcutaneous adipose tissues reach the adrenal gland via
the circulation to stimulate aldosterone release and thus
function in an endocrine manner [35, 36]. Adipose tissue
is also located on the adrenal gland and is therefore in the
proximity of adrenocortical cells, indicating that adipocyte-
derivedfactors mayalsoactinaparacrinemanner [37].Early
work by Goodfriend et al. showed in patients with visceral
obesity that aldosterone levels increased independently of
renin or K+ concentrations, suggesting the possibility that
an adipocyte-derived factor was stimulating aldosterone
secretion [38].
Obesity is associated with an increase in plasma fatty
acid and enhanced oxidative stress [39, 40]a n dh a sl e d
to the hypothesis that oxidized free fatty acids might lead
to aldosterone secretion [41]. 12,13-epoxy-9-keto-10(trans)-
octadecanoic acid (EKODE), a highly potent oxidized
derivative of linoleic acid, was found to stimulate aldos-
teroneogenesis in rat adrenal glomerulosa cells [41, 42],
and EKODE directly correlated with aldosterone levels in
h u m a ns u b j e c t sw i t ha ne l e v a t e dB M Ia n di nA f r i c a nA m e r -
icans with hypertension [41]. These ﬁndings suggest a link
between oxidative stress, aldosterone, and hypertension in
obesity.
Ehrhart-Bornstein et al. also showed that human adipo-
cytessecrete potentmineralocorticoid-releasing factor which
canactdirectlyontheadrenal glandtoincrease mineralocor-
ticoid secretion [37]. Here, conditioned media from human
derivedadipocyteswas addedtohuman derivedNCI-H295R
adrenocortical cells, and these cells increased the secretion
of mineralocorticoids including cortisol, dehydroepiandros-
terone (DHEA), and most prominently, that of aldosterone.
Although it was previously shown that Ang-II led to an
increased aldosterone secretion through interaction with the
Ang-II type-1 (AT1) receptor in NCI-H295R cells [43], AT1
antagonism with valsartan had no eﬀect on aldosterone
secretion in the fat cell-conditioned media, eliminating the
eﬀect of Ang-II. In addition to Ang-II, plasma K+ is reported
to inducealdosteronesecretion [44],butbecause K+ concen-
tration in the cell media was not diﬀerent among treatment
groups [43], K+ was ruled out as a mediator of aldosterone
release in this study [43]. Although the investigators were
unable to identify or further characterize the identity of
these adipose-derived mineralocorticoid-releasing factors,
they were able to determine that these eﬀects were not
mediated by leptin, adiponectin, IL-6, or TNF-α.I n t e r -
estingly, aldosterone may in turn promote adipogenesis
through its interaction with the mineralocorticoid receptor
(MR) [45], and although adipocytes are thought not to
synthesize aldosterone, they express the MR [46]. However,
recent data from the Touyz lab suggests that adipocytes
may produce aldosterone [47]. Thus, it is plausible that
aldosterone secretion mediated by adipose-derived factors
or “aldosterone-stimulating factors” [11, 13] may promote
further adipogenesis resulting in a vicious cycle linking
hyperaldosteronism and obesity, compounding the adverse
eﬀects of the metabolic syndrome [9]( Figure 1).
2.2. Adiponectin and Aldosterone (Figure 1). In obesity and
hypertension, aldosterone levels are increased [48], whereas
adiponectin levels are decreased [49, 50]. Evidence for
adiponectin and aldosterone crosstalk exists. In diabetic
db/db mice, inhibition of aldosterone binding to the MRs in
adipose tissue modulated obesity-related changes in cardiac
adiponectin expression [51]. Adipocytesexpress adiponectin
receptors [52], MRs [46], Ang-II type 1 receptors, and an-
giotensinogen [53], suggesting an interaction between the
RAAS and adiponectin in adipose tissue. Interestingly,
whilst the MR is also present on cardiomyocytes [54], the
adiponectin receptors, AdipoR1 and AdipoR2 [55], are also
present. It isunknown whether crosstalk betweenadiponect-
in and aldosterone occurs at the receptor level in the heart
and has not been explored.International Journal of Hypertension 3
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Figure 1: Proposed schematic representation of the interplay between adipose tissue, adrenal aldosterone production, and cardiac
remodeling in the metabolic syndrome. Aldosterone production is increased in response to molecular factors including angiotensin, K+,
and adrenocorticotropin, as well as a number of adipocyte-derived “aldosterone-stimulating factors.” Aldosterone mediates both genomic
and nongenomic eﬀects on the heart through its interaction with the mineralocorticoid receptor (MR), which may ultimately result in
adverse cardiac remodeling. In addition, aldosterone can target adipocyte-speciﬁc MRs which may enhance adipogenesis. Furthermore,
elevated aldosteronebinding to adipocyte MRsmay modulate adiponectin production. The presence ofadiponectin receptors (AdipoR1 and
AdipoR2) on the cardiomyocyte and that both aldosterone and adiponectin are synthesized in the failing human heart suggest a potential
for crosstalk between adiponectin and aldosterone in pathological conditions.
The proinﬂammatory milieu induced by aldosterone
contributes to the progression of hypertension to diastolic
HF [56, 57]. We have shown that lack of adiponectin exacer-
batestheprogression fromhypertension todiastolicHF[57].
It is likely that the eﬀect of adiponectin is not purely salutary
but represents an important interaction in the pathophys-
iology of hypertension-related cardiac disease. Although it
hasbeendemonstratedthattheheart synthesizes aldosterone
[27], it is unclear whether the heart synthesizes physio-
logical signiﬁcant amounts of aldosterone [58]; however
the MRs present on cardiomyocytes may be accessed by
both aldosterone and cortisol [59, 60]( Figure 2). Although
recent data (in abstract form) suggests that adipocytes may
produce aldosterone in both 3T3-L1 adipocytes and obese
db/db mice via activation of AT1-R [47], the majority of
ﬁndings strongly suggest that adipocytes do not synthesize
aldosterone. Although adipocytes [61]a n dc a r d i o m y o c y t e s ,
in pathological situations, synthesize adiponectin [51, 62],
only cardiomyocytes [27] appear to synthesize aldosterone.
On the other hand, it is also worth noting that adipose tissue
secretes angiotensinogen [63–65] and accounts for increased
plasma angiotensinogen levels found in obese humans [66].
Angiotensinogen has also been suggested as a link between
obesity and the development of the metabolic syndrome
[67].
Further evidence of an interaction between aldosterone
and adiponectin is provided by the following: AdipoR1
and AdipoR2 have been found in the histologically normal
human adrenal cortex and in aldosterone-producing ade-
nomas [68]. In normal subjects, a high-salt diet suppresses
RAASandincreases adiponectinlevels.Thedecreased Ang-II
levels are in proportion the decreased renin and aldosterone
levels [69]. Whilst adiponectin levels are depressed in the
metabolic syndrome where hypertension is prevalent, a
high incidence of metabolic syndrome occurs in primary
aldosteronism where hypertension is prevalent. Chronic
infusion of aldosterone in mice decreased adiponectin
production from fat in wild-type mice and was unde-
tectable in adiponectin-deﬁcient mice [57]. Similarly in vitro
experiments in aldosterone-treated adipocytes decreased
adiponectin transcript [51].Thismay beduetodirect (aldos-
terone excess) or indirect mechanisms [70]b u tt h ei n t e r a c -
tion with the receptors for aldosterone and adiponectin has
not been elucidated in the metabolic syndrome.4 International Journal of Hypertension
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Figure 2: Cortisol and aldosteronebind the MR withequal aﬃnity,
but cortisol levels are signiﬁcantly higher relative to aldosterone
and, thus, occupy these receptors. The enzyme 11β-HSD2 acts to
convert cortisol to cortisone, which is unable to bind the MR,
thus allowing aldosterone to bind the available receptors. Once
bound, the MR can translocate to the nucleus and engage DNA
promoter sites to aﬀect transcription and translation (genomic
eﬀects). Aldosterone can also mediate rapid nongenomic eﬀects
via the MR, which does not involve gene expression and protein
synthesis.
3.AldosteroneMediatesItsEffectsvia
the MineralocorticoidReceptor(MR)
Aldosteronebinds to the MR, which is a ligand-speciﬁc tran-
scription factor belonging to the steroid super-family mem-
berofreceptors[71].Evolutionarily,the MRappearedearlier
than the CYP11B2 enzyme [21, 72], suggesting that other
possible ligands existed for the MR. For example, cortisol
also serves as a potent ligand for the MR that competes
with aldosterone with equal aﬃnity [73]. However, because
cortisol concentrations are at the very least tenfold and
up to 1000-fold higher than that of aldosterone in the
cardiomyocyte [17, 74] and at least 100-fold higher in the
circulating plasma [75], it primarily will occupy the MR site.
Once cortisol is converted to its inactive form, cortisone,
by the actions of 11β hydroxysteroid dehydrogenase 2 (11β-
HSD2), aldosterone is then permitted to occupy the MR
[73]( Figure 2). Many tissues including the kidney, colon,
endothelium, and vascular smooth muscle cells express 11β-
HSD2,butthere has been controversy aboutits expression in
cardiactissue[73].Whilemanyarguethattheheartexpresses
littleifanyofthisspeciﬁcenzyme[21,59,73,76,77],Lombes
et al. has shown that the human heart does expressed 11β-
HSD2 [54]. Additionally, aldosterone has been shown to be
produced in the failing human heart by increased expression
of CYP11B2 (aldosterone synthase), the enzyme catalyzing
the terminal step in aldosterone synthesis [78].
Aldosteronemayleadtothedevelopmentofthemetabol-
ic syndrome via both genomicand nongenomic eﬀectsofthe
activated MR [79]. Increased expression of proinﬂammatory
cytokines (TNF-α, MCP-1) and prothrombotic factor PAI-1
is inhibited by the selective antagonist (eplerenone) indicat-
ing a role for MR activation and increased inﬂammation in
obese diabetic db/db mice [51]. Furthermore, MR activation
can lead to the generation of increased cardiovascular oxida-
tive stress [17, 80], which can contribute to increased cardiac
hypertrophy and ﬁbrosis associated with the metabolic
syndrome [81]. In the clinical setting, there has been a link
between MR activation, LVH and the metabolic syndrome in
humans with primary aldosteronism [15].
Upon ligation, the MR will translocate to the nucleus
where it regulates gene expression by binding to the hor-
mone/steroid response element (HRE/SRE) [82]o rn e g a t i v e
response element (nSRE) [83] DNA sequences. In addition
to its expression in kidney, colon, and brain [84, 85], the
MR is found throughout the cells in the vasculature (i.e.,
smooth muscle cells and endothelial cells) [86], on cardiac
myocytes [54, 85], and on cardiac ﬁbroblasts, where aldos-
terone induces ﬁbroblast growth through a Ras-Raf-MEK-
ERK signaling cascade activated by the MR [87]. Because
aldosterone can mediate detrimental eﬀects in the heart by
interactions with the MR, MR inhibition/antagonism is an
attractive therapeutic strategy, a topic discussed in a later
section.
Aldosterone can also mediate rapid (<5min) nonge-
nomic eﬀects that do not require transcription or protein
synthesis in order to mediate these eﬀects [22, 88]. It was
initially believed that these nongenomic eﬀects occurred
through a MR-independent mechanisms [21]. However, it is
now generally accepted that these nongenomic eﬀects may
also be mediated in part through the MR [89]. Eplerenone,
a selective MR antagonist, has been shown to inhibit
nongenomic eﬀects of aldosterone [90]. Aldosterone medi-
ates nongenomic eﬀects in many cells including vascular
smooth muscle cells and arteriole endothelial cells, as well
as in cardiomyocytes [91–93]. Eﬀects on the cardiomyocyte
include a rapid increase in Na+/K+/2Cl− cotransporter
as well as a concomitant decreased Na+/K+ pump via
a nongenomic protein kinase C-ε-( P K C - ε-) dependent
mechanism [73,93].AreducedNa+/K+ pumpactivity would
subsequently raise intracellular Ca2+ concentration, which is
known to promote prohypertrophic signaling pathways in
the cardiomyocyte [94]. In addition to a nongenomic rise in
intracellular Ca2+, aldosterone rapidly increases intracellular
Na+ concentration and cell volume in adult rat ventricular
myocytes (ARVM) [95]. Our laboratory showed that, in iso-
lated rat ventricular myocytes, aldosterone stimulated rapid
extracellular-regulated kinase (ERK) phosphorylation that
was not inhibited by RNA and protein synthesis inhibitors.
In addition, this rapid increase in ERK1/2 phosphorylation
was inhibited by spironolactone indicating that these nonge-
nomic eﬀects in cardiomyocytes were mediated by the MR
[96]. Others have shown rapid activation by aldosterone of
the prohypertrophic ERK/mitogen-activated protein kinase
(MAPK) pathway, phosphorylation of Src, Jun N-termi-
nal kinases (JNK), and the nuclear factor kappa B (NF-κB)International Journal of Hypertension 5
signaling molecules [73, 89]. In addition, aldosterone indu-
ces a rapid decrease in PKC activity in neonatal rat ven-
tricular myocytes [97]. Aldosterone also mediates rapid
nongenomic eﬀects on the electrophysiological properties
of the heart (i.e., increased monophasic action potential)
in patients with ventricular arrhythmias [98]. Interestingly,
recentevidencesuggestsan interactionbetweennongenomic
and genomic eﬀects of aldosterone, speciﬁcally with the
genomic eﬀects being dependent upon the nongenomic
[88, 89]. Non-genomic rapid ERK activation by aldosterone
enhances aldosterone’s genomicresponses in vitro, likelydue
to the induction of the MR nuclear-cytoplasmic transloca-
tion [99]. Inhibition of early aldosterone-mediated PKCα
activation also subsequently reduced MR transactivation
[100]. Thus, the nongenomic-mediated activation of the
prolonged genomic eﬀects, coupled with the rapid nonge-
nomic eﬀects themselves, suggests a synergistic response to
aldosterone [89].
4.AdverseEffectsofAldosteroneon
CardiacRemodeling
RAAS activation in hypertension is associated with LVH and
cardiac remodeling [101]. Initially LVH serves as an adaptive
or compensatory response to a pathologic stimuli such
as myocardial infarction [102], hypertension [103], and
other causes of cardiovascular oxidative stress, for example,
ischemia-reperfusion injury [104]. However, excessive LVH
can result in cardiac dysfunction [105]. Early investigations
focused on the actions of Ang-II and its receptors (AT-
1 and AT-2) in the development of LVH [106, 107],
whilst the potential for aldosterone to directly aﬀect cardiac
hypertrophy through the action of the MR was unclear.
However experimental and clinical studies began to present
data suggesting that aldosterone induced LVH and cardiac
ﬁbrosis [108–110]. These eﬀects could be attenuated by MR
antagonism with spironolactone or eplerenone indicating
the involvement of the MR [108, 111–113]. However it
was not determined whether these eﬀects were directly due
to aldosterone or to the secondary eﬀects of aldosterone.
Okoshi et al. was able to show that aldosterone directly
induced cardiac hypertrophy and atrial natriuretic peptide
(ANP) mRNA expression (a molecular marker of cardiac
hypertrophy) in cultured neonatal rat ventricular myocytes
(NRVMs) independently of Na+/K+ balance. However, MR
antagonism with spironolactone revealed that this was
dependent on binding to the MR [114]. Additionally, they
found that this involved rapid activation (≈5min) of the
ERK1/2 and JNK MAPK cascade and the PKC pathway, sug-
gesting nongenomic eﬀects of aldosterone/MR association.
In another study, transgenic mice overexpressing 11β-HSD2
in cardiomyocytes, which allows for enhanced occupation
of the MR by aldosterone (and not cortisol), exhibited
spontaneous LVH, ﬁbrosis, and subsequent heart failure and
premature death [59]. These eﬀects were independent of
blood pressure and were ameliorated by eplerenone, further
conﬁrmingtheroleoftheMRindirectaldosterone-mediated
LVH.
More recent studies have further identiﬁed aldosterone’s
direct eﬀects on the potential mechanism involved in the
development of cardiac hypertrophy. NRVMs stimulated
with aldosterone led to the interaction of the MR with
p300, a GATA4 transcriptional coactivator involved in car-
diac hypertrophy. The resultant ANP gene expression and
increase in myocyte size were attenuated by spironolac-
tone [115]. Others have shown that aldosterone-mediated
hypertrophy involves a MR-p38 MAPK-dependent pathway,
which leads to increased protein expression of cardiotropin-
1, a prohypertrophic cytokine [116], as well as increased
protein expression of IL-18 and subsequent hypertrophy,
acting through a Rho/Rho-kinase and PPAR/NF-κBp a t h w a y
[117]. Finally, aldosterone activation of the MR can increase
cardiovascular reactive oxygen species (ROS) generation via
NAD(P)H oxidase activity [96], which are known to induce
cardiac hypertrophy and remodeling [118, 119].
Cardiac ﬁbroblasts are also aﬀected by aldosterone and
further contribute to adverse hypertrophy and remodeling
by excessive proliferation, matrix deposition, and increased
matrix metalloproteinase (MMP) activity both in vitro and
in vivo[96,120–122].Aldosterone-infusedratsonahigh-salt
diet exhibited increased inﬂammation and ﬁbrosis, which
were prevented by MR inhibition [123, 124]. Increased
expression of proinﬂammatory molecules by aldosterone
acting via the MR may help to explain the potential
mechanisms involved. For example, aldosterone increases
expression of TGF-β via MR activation, which promotes
ﬁbrosis, tissueremodelingandproductionofmatrixproteins
[17]. Interestingly, aldosterone enhanced a TGF-β-mediated
downregulation of inducible nitric oxide synthase (iNOS)
and nitric oxide (NO) in a dose-dependent manner via the
MR [125]. This appears contradictory given that iNOS is
proinﬂammatory; however, long-term inhibition of iNOS
may result in cardiac ﬁbrosis suggesting that NO may play
a role in preventing ﬁbrosis [126]. In additional experi-
ments, it was found that NO acts to quench ROS through
peroxnitrite formation, which may protect against ﬁbrosis
[127]. Similarly, iNOS inhibition decreased the NO/ROS
ratio, favoring the development of ﬁbrosis. Furthermore,
decreased endothelial NOS-derived NO has been shown
previously tobe centralin the developmentofcardiovascular
disorders [128]a n dL V H[ 129]. Aldosterone also increases
the expression of plasminogen activator inhibitor (PAI)-1, a
serine protease inhibitor which is important in ﬁbrinolysis.
PAI-1 is also involved in angiogenesis and atherogenesis
[130]. PAI-1 is secreted by endothelial cells, vascular smooth
muscle cells, hepatocytes, platelets, and adipocytes [131]. In
obesity, the majority of the circulating PAI-1 is from adipose
tissue [132]. Thus, not surprisingly, in addition to elevated
aldosterone levels, obese subjects have higher levels of PAI-1
[133], as well as increased expression of endothelin-1 [134],
thatmaycontributetoenhancedcardiacﬁbrosisandcollagen
secretion.
In many cases, the MAPK intracellular signaling cascade
playsanessential roleinmediating theseresponses. Stockand
and Meszaros found that aldosterone acting through the
MR stimulates proliferation of adult rat cardiac ﬁbroblasts
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pathway [87]. Additionally, p38 MAPK cascade is central
in aldosterone-MR-mediated expression of connective tissue
growth factor (CTGF) in embryonic rat cardiomyocytes
[135].
The contribution of RAAS activation to cardiac ﬁbrosis
in the metabolic syndrome is evident not only in the con-
ditions that constitute the metabolic syndrome, such as
hypertension or insulin resistance, but also has been demon-
strated in an elegant study by Matsui et al. [136]. They
demonstrate that MR activation leads to cardiac ﬁbrosis in
an experimental model of metabolic syndrome. Metabolic
syndrome was induced by a derivative of the spontaneously
hypertensive rat (SHR) with leptin receptor deﬁciency. In
this study, MR activation with salt caused LV diastolic
dysfunction and cardiac ﬁbrosis. Increased oxidative stress
and enhanced MR activation accelerated the pathogenesis of
salt-induced diastolic dysfunction in this model ofmetabolic
syndrome [136].
5.Treatments/MRAntagonists
Several therapeutic strategies are being applied to alleviate
the adverse eﬀects of aldosterone in cardiovascular disorders
associated with cardiac hypertrophy and ﬁbrosis. While
the use of angiotensin converting enzyme (ACE) inhibitors
in heart failure patients reduces plasma aldosterone levels,
this is only a temporary eﬀect (referred to as “aldosterone
escape”), as even maximal doses of ACE inhibitors are
associated with increased Ang-II and aldosterone levels, and
were accompanied by impaired exercise capacity [137, 138].
Two important clinical trials, the Randomized Aldosterone
Evaluation Study (RALES) [139] and the Eplerenone Heart
Failure and Survival Study (EPHESUS) [140], demonstrated
that addition of MR antagonists to ACE inhibitors reduced
mortality in patients with LV systolic dysfunction and
postmyocardial infarction with heart failure, respectively. In
additiontotheseﬁndings, further experimental investigation
into MR antagonism by such pharmacological agents as
spironolactone and eplerenone that may prevent cardiac
complicationsin patientshas provedpromising [15, 16]with
ongoing trials being explored in patients with diastolic HF.
In vitro studies demonstrated that spironolactone inhibited
aldosterone-induced [14C]-phenylalanine incorporation in
NRVMs [114] and aldosterone-induced [3H]-thymidine
incorporation in adult rat cardiac ﬁbroblasts [87]. Likewise,
in vivo experimental studies showed that spironolactone
prevented ventricular ﬁbrosis [141]. Eplerenone also atten-
uated LVH in clinical trials and may be a more attractive
therapy, because of its fewer side eﬀects compared to
spironolactone [137, 142]. Our laboratory has previously
reported that eplerenone treatment in mice subjected to
ascending aortic constriction (a model for chronic pressure
overload) improved LVH, indirectly linking the involvement
of aldosterone with chronic pressure overload [80]. It was
noted that, because aldosterone-mediated LVH and ﬁbrosis
and was in part due to increased oxidative stress and
i n ﬂ a m m a t i o n ,i ti sp o s s i b l et h a tt h eb e n e ﬁ c i a le ﬀects of
eplerenone may be due to a reduction in oxidative stress
[143, 144]. Additionally, aldosterone antagonists can work
to downregulate MMP activity [96]. In the RALES study,
spironolactone-treated patientshadreducedmatrix turnover
and ﬁbrosis, which has appeared to be the most important
eﬀect of spironolactone in the heart [137, 139].
RAAS blockade with angiotensin receptor blockers
(ARBs) and ACE inhibition have all been shown to mitigate
the adverse hemodynamic and remodeling eﬀects in several
animal models of obesity [145–148]. For example, losartan,
an AT1 receptor antagonist, improved cardiac function via
a PKB/Akt-dependent mechanism in a rat model of diet-
induced obesity [145]. Similarly, candesartan, another ARB,
when used in combination with pioglitazone, a PPAR-
γ agonist, decreased inﬂammation, oxidative stress, and
ﬁbrosis in obese, type 2 diabetic mice [148]. ACE inhibition
with captopril restored insulin signaling, improved fatty acid
oxidation and glycolysis regulation, and improved energy
statusbyreducing AMPKactivity inhearts fromobese ob/ob
mice [146]. Enalapril, another ACE inhibitor, reduced blood
pressure and improved autonomic dysfunction in obese
ob/obmice[147].Theeﬀectsseenwithenalaprilweresimilar
to those seen after leptin replacement in these mice [147].
Other therapeutic strategies against the development of
aldosterone-induced cardiac remodeling that target other
potential pathways have been explored. Past work from our
laboratoryhaslookedatfenoﬁbrate,aPPAR-αagonist,which
has been reported to suppress NF-κB activity, macrophage
recruitment, and the development of cardiac dysfunc-
tion [149–151]. Furthermore, fenoﬁbrate inhibits ERK1/2
kinase phosphorylation and MMP activity in aldosterone-
stimulated isolated ARVMs [152]. Further in vivo work has
shown that fenoﬁbrate decreases LVH, matrix turnover, and
ﬁbrosis, as well as improved LV chamber size and function
[153].
Currently, there are several clinical trials underway ex-
ploring aldosterone inhibition in obesity. These include
modulation of RAAS activity and lipid/carbohydrate me-
tabolism in adipose and skeletal muscle tissue in obese
patients with hypertension (http://www.clinicaltrials.gov/,
NCT00498433).Also,investigatorsare exploring aldosterone
inhibition in obesity speciﬁcally addressing endothelial and
ﬁbrinolytic dysfunction and measuring PAI-1 levelsto deter-
mine if there is a reduction in the risk of stroke in obesity
(http://www.clinicaltrials.gov/, NCT00608465).
6.Summary
Obesity and its association with other factors of the meta-
bolic syndrome (speciﬁcally hypertension and insulin resis-
tance) remain a signiﬁcant and growing problem among
the population. Adverse cardiac remodeling can further
contribute to these cardiovascular complications, resulting
in a vicious cycle that may ultimately lead to heart failure.
Furthermore, an association between adipose tissue and
aldosterone is evident, as adipocytes release factors (such
as “aldosterone-stimulating factors” and adipokines) that
directly or indirectly stimulate aldosterone secretion. Much
work has explored the role that hypertension and the RAASInternational Journal of Hypertension 7
(in particular of Ang-II) has on adverse cardiac remodeling,
as new insights have emerged aboutthe direct eﬀectofaldos-
teroneontheMR(nongenomicand/orgenomic).WhilstMR
antagonists have been important therapeutic tools against
cardiac hypertrophy and ﬁbrosis, further understanding
of the intricate relationship between obesity, aldosterone,
and adverse cardiac remodeling may yield more eﬀective
therapeutic treatments.
Acknowledgments
E. E. Essick is supported by funding from the National Insti-
tutes of Health (NIH) T32HL007224, and F. Sam is sup-
ported by funding from the NIH HL079099, HL095891, and
HL102631.
References
[1] N. M.Kaplan,“The deadly quartet. Upper-body obesity, glu-
cose intolerance, hypertriglyceridemia, and hypertension,”
Archives of Internal Medicine, vol. 149, no. 7, pp. 1514–1520,
1989.
[2] G. Mul` e and G. Cerasola, “The metabolic syndrome and its
relationship to hypertensive target organ damage,” Journal of
Clinical Hypertension, vol. 8, no. 3, pp. 195–201, 2006.
[ 3 ]S .M .G r u n d y ,H .B .B r e w e r ,J .I .C l e e m a n ,S .C .S m i t h ,
and C. Lenfant, “Deﬁnition of metabolic syndrome: report
of the National Heart, Lung, and Blood Institute/American
Heart Association conference on scientiﬁc issues related to
deﬁnition,”Arteriosclerosis, Thrombosis,andVascular Biology,
vol. 24, no. 2, pp. e13–e18, 2004.
[ 4 ] R .H .E c k e l ,S .M .G r u n d y ,a n dP .Z .Z i m m e t ,“ T h em e t a b o l i c
syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428,
2005.
[5] E. S. Ford, “Risks for all-cause mortality, cardiovascular dis-
ease, and diabetes associated with the metabolic syndrome: a
summary of the evidence,” Diabetes Care, vol. 28, no. 7, pp.
1769–1778, 2005.
[6] B. Isomaa, P. Almgren, T. Tuomi et al., “Cardiovascular
morbidity and mortality associated with the metabolic
syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001.
[7] H.N. Ginsberg andP.R. Maccallum,“The obesity, metabolic
syndrome, and type 2 diabetes mellitus pandemic: part I.
Increased cardiovascular disease risk and the importance
of atherogenic dyslipidemia in persons with the metabolic
syndrome and type 2 diabetes mellitus,” Journal of the
CardioMetabolic Syndrome, vol. 4, no. 2, pp. 113–119, 2009.
[8] Y. W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R.
Carnethon,and S. B. Heymsﬁeld, “The metabolic syndrome:
prevalence and associated risk factor ﬁndings in the US
population from the Third National Health and Nutri-
tion Examination Survey, 1988–1994,” Archives of Internal
Medicine, vol. 163, no. 4, pp. 427–436, 2003.
[9] A. Whaley-Connell, M. S. Johnson, and J. R. Sowers,
“Aldosterone: role in the cardiometabolic syndrome and
resistant hypertension,” Progress in Cardiovascular Diseases,
vol. 52, no. 5, pp. 401–409, 2010.
[10] A.S.BombackandP.J.Klemmer,“Interaction ofaldosterone
and extracellular volume in the pathogenesis of obesity-
associated kidney disease: a narrative review,” American
Journal of Nephrology, vol. 30, no. 2, pp. 140–146, 2009.
[ 1 1 ]M .N a g a s e ,S .Y o s h i d a ,S .S h i b a t ae ta l . ,“ E n h a n c e da l d o s -
terone signaling in the early nephropathy of rats with
metabolic syndrome: possible contribution of fat-derived
factors,” J o u r n a lo ft h eA m e r i c a nS o c i e t yo fN e p h r o l o g y ,v o l .
17, no. 12, pp. 3438–3446, 2006.
[12] M.Bochud,J.Nussberger,P.Bovetetal.,“Plasmaaldosterone
is independently associated with the metabolic syndrome,”
Hypertension, vol. 48, no. 2, pp. 239–245, 2006.
[13] D. A. Calhoun and K. Sharma, “The role of aldosteronism
in causing obesity-related cardiovascular risk,” Cardiology
Clinics, vol. 28, no. 3, pp. 517–527, 2010.
[14] J. E. Hall, “The renin-angiotensin system: renal actions and
blood pressure regulation,” Comprehensive Therapy, vol. 17,
no. 5, pp. 8–17, 1991.
[15] G. Giacchetti, F. Turchi, M. Boscaro, and V. Ronconi,
“Management of primary aldosteronism: its complications
and their outcomes after treatment,” Current Vascular Phar-
macology, vol. 7, no. 2, pp. 244–249, 2009.
[16] T. R. Marcy and T. L. Ripley, “Aldosterone antagonists in
the treatment of heart failure,” American Journal of Health-
System Pharmacy, vol. 63, no. 1, pp. 49–58, 2006.
[17] A. M. Marney and N. J. Brown, “Aldosterone and end-organ
damage,” Clinical Science, vol. 113, no. 5-6, pp. 267–278,
2007.
[18] J. Xu, O. A. Carretero, T.-D. Liao et al., “Local angiotensin
II aggravates cardiac remodeling in hypertension,” American
Journal of Physiology, vol. 299, no. 5, pp. H1328–H1338,
2010.
[ 1 9 ]M .P a u l ,A .P .M e h r ,a n dR .K r e u t z ,“ P h y s i o l o g yo fl o c a l
renin-angiotensinsystems,”PhysiologicalReviews,vol.86,no.
3, pp. 747–803, 2006.
[ 2 0 ] E .M o r n e t ,J .D u p o n t ,A .V i t e k ,a n dP .C .W h i t e ,“ C h a r a c t e r i -
zationoftwogenesencoding humansteroid11β-hydroxylase
(P-450(11β)),” Journal of Biological Chemistry, vol. 264, no.
35, pp. 20961–20967, 1989.
[21] J. W. Funder, “Minireview: aldosterone and mineralocorti-
coid receptors: past, present, and future,” Endocrinology,v o l .
151, no. 11, pp. 5098–5102, 2010.
[22] F. K. Shieh, E. Kotlyar, and F. Sam, “Aldosterone and
cardiovascular remodelling: focus on myocardial failure,”
Journal of the Renin-Angiotensin-Aldosterone System,v o l .5 ,
no. 1, pp. 3–13, 2004.
[23] T. Tsutamoto, A. Wada, K. Maeda et al., “Spironolactone
inhibits the transcardiac extraction ofaldosteronein patients
with congestive heart failure,” Journal of the American College
of Cardiology, vol. 36, no. 3, pp. 838–844, 2000.
[ 2 4 ]J .C .X i u ,P .W u ,J .P .X ue ta l . ,“ E ﬀects of long-term enalapril
and losartan therapy of heart failure on cardiovascular
aldosterone,”JournalofEndocrinologicalInvestigation,vol.25,
no. 5, pp. 463–468, 2002.
[25] A. E. Rudolph, E. R. Blasi, and J. A. Delyani, “Tissue-speciﬁc
corticosteroidogenesis in the rat,” Molecular and Cellular
Endocrinology, vol. 165, no. 1-2, pp. 221–224, 2000.
[ 2 6 ]P .Y e ,C .J .K e n y o n ,S .M .M a c K e n z i ee ta l . ,“ T h ea l d o s t e r o n e
synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) genes
are not expressed in the rat heart,” Endocrinology, vol. 146,
no. 12, pp. 5287–5293, 2005.
[27] M. J. Young, C. D. Clyne, T. J. Cole, and J. W. Funder, “Car-
diac steroidogenesis in the normaland failing heart,” Journal
of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp.
5121–5126, 2001.
[28] T. Tsutamoto,A. Wada, K. Maeda et al., “Transcardiac gradi-
ent ofaldosteronebefore andafter spironolactoneinpatients8 International Journal of Hypertension
with congestive heart failure,” Journal of Cardiovascular
Pharmacology, vol. 41, supplement 1, pp. S19–S22, 2003.
[29] E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E.
Gomez-Sanchez, “Origin of aldosterone in the rat heart,”
Endocrinology, vol. 145, no. 11, pp. 4796–4802, 2004.
[ 3 0 ]K .M .K a y e s - W a n d o v e ra n dP .C .W h i t e ,“ S t e r o i d o g e n i c
enzyme gene expression in the human heart,” Journal of
Clinical Endocrinology and Metabolism,v o l .8 5 ,n o .7 ,p p .
2519–2525, 2000.
[ 3 1 ]M .E h r h a r t - B o r n s t e i n ,J .P .H i n s o n ,S .R .B o r n s t e i n ,W .A .
Scherbaum, and G. P. Vinson, “Intraadrenal interactions in
the regulation of adrenocortical steroidogenesis,” Endocrine
Reviews, vol. 19, no. 2, pp. 101–143, 1998.
[32] C. Marx, M. Ehrhart-Bornstein, W. A. Scherbaum, and
S. R. Bornstein, “Regulation of adrenocortical function by
cytokines—relevance for immune-endocrine interaction,”
Hormone and Metabolic Research, vol. 30, no. 6-7, pp. 416–
420, 1998.
[33] S. P. Poulos,D. B. Hausman,and G. J. Hausman,“The devel-
opment and endocrine functions of adipose tissue,” Molec-
ular and Cellular Endocrinology, vol. 323, no. 1, pp. 20–34,
2010.
[34] Y. E. Bogaert and S. Linas, “The role of obesity in the patho-
genesisofhypertension,” Nature Clinical Practice Nephrology,
vol. 5, no. 2, pp. 101–111, 2009.
[35] S. Kim and N. Moustaid-Moussa, “Secretory, endocrine and
autocrine/paracrine function of the adipocyte,” Journal of
Nutrition, vol. 130, no. 12, pp. 3110S–3115S, 2000.
[36] P. Trayhurn and J. H. Beattie, “Physiological role of adipose
tissue: white adipose tissue as an endocrine and secretory
organ,” Proceedings of the Nutrition Society,v o l .6 0 ,n o .3 ,p p .
329–339, 2001.
[37] M. Ehrhart-Bornstein, V. Lamounier-Zepter, A. Schraven et
al., “Human adipocytes secrete mineralocorticoid-releasing
factors,”Proceedings of the National Academyof Sciencesof the
United States of America, vol. 100, no. 2, pp. 14211–14216,
2003.
[38] T. L. Goodfriend, B. M. Egan, and D. E. Kelley, “Aldosterone
in obesity,” Endocrine Research, vol. 24, no. 3-4, pp. 789–796,
1998.
[ 3 9 ]J .F .K e a n e y ,M .G .L a r s o n ,R .S .V a s a ne ta l . ,“ O b e s i t ya n d
systemicoxidative stress: clinical correlates of oxidative stress
in the Framingham study,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 23, no. 3, pp. 434–439, 2003.
[40] P. Surya Prabha, U. N. Das, R. Koratkar, P. S. Sagar, and
G. Ramesh, “Free radical generation, lipid peroxidation and
essential fatty acids in uncontrolled essential hypertension,”
Prostaglandins Leukotrienes and Essential Fatty Acids,v o l .4 1 ,
no. 1, pp. 27–33, 1990.
[ 4 1 ]T .L .G o o d f r i e n d ,D .L .B a l l ,B .M .E g a n ,W .B .C a m p b e l l ,
and K. Nithipatikom, “Epoxy-keto derivative of linoleic acid
stimulates aldosterone secretion,” Hypertension,v o l .4 3 ,n o .
2, pp. 358–363, 2004.
[42] H. W. Gardner and C. G. Crawford, “Degradation of linoleic
acid hydroperoxides by a cysteine. FeCl3 catalyst as a model
for similar biochemical reactions. III. A novel product,
trans-12,13-epoxy-11-oxo-trans-9-octadecenoic acid, from
13-L(S)-hydroperoxy-cis-9,trans-11-octadecadienoic acid,”
Biochimica et Biophysica Acta, vol. 665, no. 1, pp. 126–133,
1981.
[43] U. Hilbers, J. Peters, S. R. Bornstein et al., “Local renin-
angiotensin system is involved in K+-induced aldosterone
secretion from human adrenocortical NCI-H295 cells,”
Hypertension, vol. 33, no. 4, pp. 1025–1030, 1999.
[44] S. J. Quinn and G. H. Williams, “Regulation of aldosterone
secretion,” Annual Review of Physiology, vol.50, pp. 409–426,
1988.
[ 4 5 ]M .C a p r i o ,B .F ` eve, A. Cla¨ es, S. Viengchareun, M. Lomb` es,
and M. C. Zennaro, “Pivotal role of the mineralocorticoid
receptor in corticosteroid-induced adipogenesis,” FASEB
Journal, vol. 21, no. 9, pp. 2185–2194, 2007.
[46] T. L. Pascual-Le and M. Lomb` es, “The mineralocorticoid
receptor: a journey exploring its diversity and speciﬁcity of
action,” Molecular Endocrinology, vol. 19, no. 9, pp. 2211–
2221, 2005.
[47] A. M. Briones, A. N. Dinh Cat, G. E. Callera et al., “Produc-
tion of aldosterone by adipocytes: implications for obesity
and vascular function,” Hypertension, vol. 56, article e73,
2010.
[48] D. A. Calhoun, “Aldosteronism and hypertension,” Clinical
Journal of the American Society of Nephrology,v o l .1 ,n o .5 ,
pp. 1039–1045, 2006.
[49] Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease
of an adipose-speciﬁc protein, adiponectin, in obesity,”
Biochemical and Biophysical Research Communications,v o l .
257, no. 1, pp. 79–83, 1999.
[50] Y. Iwashima, T. Katsuya, K. Ishikawa et al., “Hypoad-
iponectinemia is an independent risk factor for hyperten-
sion,” Hypertension, vol. 43, no. 6, pp. 1318–1323, 2004.
[ 5 1 ]C .G u o ,V .R i c c h i u t i ,B .Q .L i a ne ta l . ,“ M i n e r a l o c o r t i -
coid receptor blockade reverses obesity-related changes in
expression of adiponectin, peroxisome proliferator-activated
receptor-γ, and proinﬂammatory adipokines,” Circulation,
vol. 117, no. 17, pp. 2253–2261, 2008.
[52] M. Beylot, C. Pinteur, and O. Peroni, “Expression of the
adiponectin receptors AdipoR1 andAdipoR2 in lean ratsand
inobeseZuckerrats,”Metabolism,vol.55,no.3,pp.396–401,
2006.
[53] A. Saiki, M. Ohira, K. Endo et al., “Circulating angiotensin
II is associated with body fat accumulation and insulin
resistance in obese subjects with type 2 diabetes mellitus,”
Metabolism, vol. 58, no. 5, pp. 708–713, 2009.
[54] M. Lombes, N. Alfaidy, E. Eugene, A. Lessana, N. Farman,
and J. P. Bonvalet, “Prerequisite for cardiac aldosterone
action: mineralocorticoid receptor and 11β-hydroxysteroid
dehydrogenase in the human heart,” Circulation, vol. 92, no.
2, pp. 175–182, 1995.
[ 5 5 ]G .D i n g ,Q .Q i n ,N .H ee ta l . ,“ A d i p o n e c t i na n di t s
receptors are expressed in adult ventricular cardiomyocytes
and upregulated by activation of peroxisome proliferator-
activated receptor γ,” Journal of Molecular and Cellular
Cardiology, vol. 43, no. 1, pp. 73–84, 2007.
[ 5 6 ]R .M .W i l s o n ,D .S .D eS i l v a ,K .S a t o ,Y .I z u m i y a ,a n dF .
Sam, “Eﬀects of ﬁxed-dose isosorbide dinitrate/hydralazine
on diastolic function and exercise capacity in hypertension-
induced diastolic heart failure,” Hypertension,v o l .5 4 ,n o .3 ,
pp. 583–590, 2009.
[57] F. Sam, T. A. S. Duhaney, K. Sato et al., “Adiponectin
deﬁciency, diastolic dysfunction, and diastolic heart failure,”
Endocrinology, vol. 151, no. 1, pp. 322–331, 2010.
[58] C. E. Gomez-Sanchez, M. F. Foecking, and E. P. Gomez-
Sanchez,“Aldosteroneestersandtheheart,”American Journal
of Hypertension, vol. 14, no. 6, 2001.
[59] W. Qin, A. E. Rudolph, B. R. Bond et al., “Transgenic model
of aldosterone-driven cardiac hypertrophy andheart failure,”
Circulation Research, vol. 93, no. 1, pp. 69–76, 2003.International Journal of Hypertension 9
[60] A. Mano, T. Tatsumi, J. Shiraishi et al., “Aldosterone directly
induces myocyte apoptosis through calcineurin-dependent
pathways,” Circulation, vol. 110, no. 3, pp. 317–323, 2004.
[61] N. Ouchi, S. Kihara, Y. Arita et al., “Novel modulator for
endothelial adhesion molecules: adipocyte-derived plasma
protein adiponectin,” Circulation, vol. 100, no. 25, pp. 2473–
2476, 1999.
[62] R. Pi˜ neiro, M. J. Iglesias, R. Gallego et al., “Adiponectin is
synthesized and secreted by human and murine cardiomy-
ocytes,” FEBS Letters, vol. 579, no. 23, pp. 5163–5169, 2005.
[63] V. DeClercq, C. Taylor, and P. Zahradka, “Adipose tissue: the
link between obesity and cardiovascular disease,” Cardiovas-
cular and Hematological Disorders—Drug Targets,v o l .8 ,n o .
3, pp. 228–237, 2008.
[64] L.Gilardini,A.Zulian,A.Girola,G.R edaelli,A.Conti,andC.
Invitti,“Predictors oftheearlyimpairmentofrenaldiseasein
human obesity,” International Journal of Obesity, vol. 34, no.
2, pp. 287–294, 2010.
[65] S. Engeli, P. Schling, K. Gorzelniak et al.,“The adipose-tissue
renin-angiotensin-aldosterone system: role in the metabolic
syndrome?” International Journal of Biochemistry and Cell
Biology, vol. 35, no. 6, pp. 807–825, 2003.
[66] S. Yasue, H. Masuzaki, S. Okada et al., “Adipose tissue-
speciﬁc regulation of angiotensinogen in obese humans and
mice: impact of nutritional status and adipocyte hypertro-
phy,” American Journal of Hypertension,v o l .2 3 ,n o .4 ,p p .
425–431, 2010.
[ 6 7 ]M .A .Z u l e t ,B .P u c h a u ,C .N a v a r r o ,A .M a r t ´ ı, and J.
A. Mart´ ınez Hern´ andez, “Inﬂammatory biomarkers: the
link between obesity and associated pathologies,” Nutricion
Hospitalaria, vol. 22, no. 5, pp. 511–527, 2007.
[68] G.P.Rossi,D.Sticchi,L.Giulianietal.,“Adiponectin receptor
expression in the human adrenal cortex and aldosterone-
producing adenomas,” International Journal of Molecular
Medicine, vol. 17, no. 6, pp. 975–980, 2006.
[ 6 9 ]A .T .L e l y ,J .A .K r i k k e n ,S .J .L .B a k k e re ta l . ,“ L o wd i e t a r y
sodium and exogenous angiotensin II infusion decrease
plasma adiponectin concentrations in healthy men,” Journal
of Clinical Endocrinology and Metabolism,v o l .9 2 ,n o .5 ,p p .
1821–1826, 2007.
[70] F. Fallo, P. Della Mea, N. Sonino et al., “Adiponectin and
insulin sensitivity in primary aldosteronism,”American Jour-
nal of Hypertension, vol. 20, no. 8, pp. 855–861, 2007.
[71] J. W. Funder, “Aldosterone and mineralocorticoid receptors
in the cardiovascular system,” Progress in Cardiovascular
Diseases,vol. 52, no. 5, pp. 393–400, 2010.
[72] X. Hu and J.W. Funder, “The evolutionofmineralocorticoid
receptors,” Molecular Endocrinology, vol. 20, no. 7, pp. 1471–
1478, 2006.
[73] A. Tirosh, R. Garg, and G. K. Adler, “Mineralocorticoid
receptor antagonists and the metabolic syndrome,” Current
Hypertension Reports, vol. 12, pp. 252–257, 2010.
[74] A. S. Mihailidou and J. W. Funder, “Nongenomic eﬀects of
mineralocorticoid receptor activation in the cardiovascular
system,” Steroids, vol. 70, no. 5–7, pp. 347–351, 2005.
[75] O. Muller, S. Pradervand, S. Berger et al., “Identiﬁcation of
corticosteroid-regulated genes in cardiomyocytes by serial
analysisofgeneexpression,”Genomics,vol.89,no.3,pp.370–
377, 2007.
[76] W. Chai and A. H. J. Danser, “Why are mineralocorticoid
receptor antagonists cardioprotective?” Naunyn-Schmiede-
berg’s Archives of Pharmacology, vol. 374, no. 3, pp. 153–162,
2006.
[77] K. Nagata, K. Obata, J. Xu et al., “Mineralocorticoid receptor
antagonism attenuates cardiac hypertrophy and failure in
low-aldosterone hypertensive rats,” Hypertension, vol.47, no.
4, pp. 656–664, 2006.
[78] M. Yoshimura, S. Nakamura, T. Ito et al., “Expression of
aldosterone synthase gene in failing human heart: quanti-
tative analysis using modiﬁed real-time polymerase chain
reaction,” Journal of Clinical Endocrinology and Metabolism,
vol. 87, no. 8, pp. 3936–3940, 2002.
[79] M. Briet and E. L. Schiﬀrin, “The role of aldosterone in the
metabolic syndrome,” Current Hypertension Reports, vol. 13,
no. 2, pp. 163–172, 2011.
[ 8 0 ]G .M .K u s t e r ,E .K o t l y a r ,M .K .R u d ee ta l . ,“ M i n e r a l o c o r t i -
coid receptor inhibition ameliorates the transition to myo-
cardial failure and decreases oxidative stress and inﬂamma-
tion in micewith chronic pressure overload,” Circulation,v o l .
111, no. 4, pp. 420–427, 2005.
[81] S. Delbosc, E. Paizanis, R. Magous et al., “Involvement of
oxidative stress and NADPH oxidase activation in the devel-
opmentofcardiovascularcomplicationsinamodelofinsulin
resistance, the fructose-fed rat,” Atherosclerosis, vol. 179, no.
1, pp. 43–49, 2005.
[82] D. J.Mangelsdorf,C.Thummel,M.Beato et al.,“The nuclear
receptor super-family: the seconddecade,” Cell,vol.83,no.6,
pp. 835–839, 1995.
[83] R. E. Booth, J. P. Johnson,and J. D. Stockand, “Aldosterone,”
American Journal of Physiology, vol. 26, no. 1–4, pp. 8–20,
2002.
[84] J. P. Bonvalet, “Regulation of sodium transport by steroid
hormones,” Kidney International, vol. 53, no. 65, pp. S49–
S56, 1998.
[85] P.PearceandJ.W.Funder,“Highaﬃnityaldosteronebinding
sites(typeIreceptors) inratheart,”ClinicalandExperimental
Pharmacology and Physiology,vol.14,no.11-12,pp.859–866,
1987.
[86] Y. Takeda, I. Miyamori, S. Inaba et al., “Vascular aldosterone
in genetically hypertensive rats,” Hypertension,v o l .2 9 ,n o .1 ,
pp. 45–48, 1997.
[87] J. D. Stockand and J. G. Meszaros, “Aldosterone stimulates
proliferation of cardiac ﬁbroblasts by activating Ki-RasA and
MAPK1/2 signaling,” American Journal of Physiology,v o l .
284, no. 1, pp. H176–H184, 2003.
[88] T. Y. Chun and J. H. Pratt, “Non-genomic eﬀects of aldos-
terone: new actions and questions,” Trends in Endocrinology
and Metabolism, vol. 15, no. 8, pp. 353–354, 2004.
[89] C. Grossmann and M. Gekle, “New aspects of rapid aldos-
terone signaling,” Molecular and Cellular Endocrinology,v o l .
308, no. 1-2, pp. 53–62, 2009.
[90] L.M ic he a,A .M.D e lp iano ,C .H it sc hf e ld ,L.Lob os,S.La v an-
dero, and E. T. Marusic, “Eplerenone blocks nongenomic
eﬀects of aldosterone on the Na+/H+ exchanger, intracellular
Ca2+ levels, and vasoconstriction in mesenteric resistance
vessels,” Endocrinology, vol. 146, no. 3, pp. 973–980, 2005.
[91] S. L. Liu, S. Schmuck, J. Z. Chorazcyzewski, R. Gros, and R.
D.Feldman,“Aldosteroneregulates vascularreactivity: short-
term eﬀects mediated by phosphatidylinositol 3-kinase-
dependent nitric oxide synthase activation,” Circulation,v o l .
108, no. 19, pp. 2400–2406, 2003.
[ 9 2 ]T .R .U h r e n h o l t ,J .S c h j e r n i n g ,P .B .H a n s e ne ta l . ,“ R a p i d
inhibition of vasoconstriction in renal aﬀerent arterioles by
aldosterone,” Circulation Research, vol. 93, no. 12, pp. 1258–
1266, 2003.10 International Journal of Hypertension
[93] A. S. Mihailidou, M. Mardini, and J. W. Funder, “Rapid,
nongenomiceﬀects of aldosterone in the heart mediated by ε
protein kinaseC,” Endocrinology,vol.145,no.2,pp.773–780,
2004.
[94] J. Heineke and J. D. Molkentin, “Regulation of cardiac
hypertrophy by intracellular signalling pathways,” Nature
Reviews Molecular Cell Biology, vol. 7, no. 8, pp. 589–600,
2006.
[95] S. Matsui, H. Satoh, H. Kawashima et al., “Non-genomic
eﬀects of aldosterone on intracellular ion regulation and cell
volume in rat ventricular myocytes,” Canadian Journal of
Physiology and Pharmacology, vol. 85, no. 2, pp. 264–273,
2007.
[ 9 6 ]M .K .R u d e ,T .A .S .D u h a n e y ,G .M .K u s t e re ta l . ,“ A l d o s -
terone stimulates matrix metalloproteinases and reactive
oxygen species in adult rat ventricular cardiomyocytes,”
Hypertension, vol. 46, no. 3, pp. 555–561, 2005.
[ 9 7 ]A .S a t o ,J .P .L i u ,a n dJ .W .F u n d e r ,“ A l d o s t e r o n er a p i d l y
represses protein kinase C activity in neonatal rat cardiomy-
ocytes invitro,”Endocrinology,vol.138,no.8,pp.3410–3416,
1997.
[98] H. C. Tillmann, B. Schumacher, O. Yasenyev et al., “Acute
eﬀects of aldosterone on intracardiac monophasic action
potentials,” International Journal of Cardiology, vol. 84, no.
1, pp. 33–39, 2002.
[99] C. Grossmann,A. Benesic, A.W. Krug et al.,“Human miner-
alocorticoid receptor expression renders cells responsive for
nongenotropic aldosterone actions,” Molecular Endocrinol-
ogy, vol. 19, no. 7, pp. 1697–1710, 2005.
[100] C. Le Mo¨ ellic, A. Ouvrard-Pascaud, C. Capurro et al., “Early
nongenomic events in aldosterone action in renal collect-
ing duct cells: PKCα activation, mineralocorticoid receptor
phosphorylation,and cross-talk with the genomicresponse,”
Journal of the American Society of Nephrology,v o l .1 5 ,n o .5 ,
pp. 1145–1160, 2004.
[101] T. K. W. Ma, K. K. H. Kam, B. P. Yan, and Y. Y. Lam, “Renin-
angiotensin-aldosterone system blockade for cardiovascular
diseases:current status,”British Journal of Pharmacology,v o l .
160, no. 6, pp. 1273–1292, 2010.
[102] J. A. Byrne, D. J. Grieve, A. C. Cave, and A. M. Shah,
“Oxidative stress and heart failure,” Archives des Maladies du
Coeur et des Vaisseaux, vol. 96, no. 3, pp. 214–221, 2003.
[103] L. C. Matavelli, X. Zhou, and E. D. Frohlich, “Hypertensive
renalvasculardiseaseandcardiovascularendpoints,”Current
Opinion in Cardiology, vol. 21, no. 4, pp. 305–309, 2006.
[104] D. J. Grieve, J. A. Byrne, A. C. Cave, and A. M. Shah, “Role
of oxidative stress in cardiac remodelling after myocardial
infarction,” Heart Lung and Circulation,v o l .1 3 ,n o .2 ,p p .
132–138, 2004.
[105] N. S. Dhalla, H. K. Saini-Chohan, D. Rodriguez-Leyva,
V. Elimban, M. R. Dent, and P. S. Tappia, “Subcellular
remodelling may induce cardiac dysfunction in congestive
heartfailure,”Cardiovascular Research,vol.81,no.3,pp.429–
438, 2009.
[106] J. I. Sadoshima and S. Izumo, “Molecular characterization
of angiotensin II-induced hypertrophy of cardiac myocytes
and hyperplasia of cardiac ﬁbroblasts: critical role of the AT1
receptor subtype,” Circulation Research,v o l .7 3 ,n o .3 ,p p .
413–423, 1993.
[107] B. H. Lorell, “Role of angiotensin AT1 and AT2 receptors
in cardiac hypertrophy and disease,” American Journal of
Cardiology, vol. 83, no. 12A, pp. 48H–52H, 1999.
[108] Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, and H.
Mabuchi, “Cardiac aldosterone production in genetically
hypertensive rats,” Hypertension, vol. 36, no. 4, pp. 495–500,
2000.
[109] S. Kagiyama, K. Matsumura, M. Fukuhara, K. Sakagami,
K. Fujii, and M. Iida, “Aldosterone-and-salt-induced cardiac
ﬁbrosis is independent from angiotensin II type 1a receptor
signaling in mice,” Hypertension Research, vol. 30, no. 10, pp.
979–989, 2007.
[110] K. Matsumura, K. Fujii, H. Oniki, M. Oka, and M. Iida,
“Role of aldosterone in left ventricular hypertrophy in
hypertension,” American Journal of Hypertension,v o l .1 9 ,n o .
1, pp. 13–18, 2006.
[111] G. Suzuki, H. Morita, T. Mishima et al., “Eﬀects of long-
term monotherapy with eplerenone, a novel aldosterone
blocker, on progression of left ventricular dysfunction and
remodeling in dogs with heart failure,” Circulation, vol. 106,
no. 23, pp. 2967–2972, 2002.
[112] M. Hayashi, T. Tsutamoto, A. Wada et al., “Immediate
administration of mineralocorticoid receptor antagonistspi-
ronolactone prevents post-infarct left ventricular remodeling
associated with suppression of a marker of myocardial colla-
gen synthesis in patients with ﬁrst anterior acute myocardial
infarction,” Circulation, vol. 107, no. 20, pp. 2559–2565,
2003.
[113] B. Pitt, N. Reichek, R. Willenbrock et al., “Eﬀects of epleren-
one, enalapril, and eplerenone/enalapril in patients with
essential hypertension and left ventricular hypertrophy: the
4E-left ventricular hypertrophy study,” Circulation, vol. 108,
no. 15, pp. 1831–1838, 2003.
[114] M. P. Okoshi, X. Yan, K. Okoshi et al., “Aldosterone directly
stimulates cardiac myocyte hypertrophy,” Journal of Cardiac
Failure, vol. 10, no. 6, pp. 511–518, 2004.
[115] Y. Yoshida, T. Morimoto, T. Takaya et al., “Aldosterone sig-
naling associates with p300/GATA4 transcriptional pathway
during the hypertrophic response of cardiomyocytes,” Circu-
lation Journal, vol. 74, no. 1, pp. 156–162, 2010.
[116] N. L´ opez-Andr´ es, C. I˜ nigo, I. Gallego, J. D´ ıez, and M. A.
Fortu˜ no,“Aldosteroneinduces cardiotrophin-1expression in
HL-1 adult cardiomyocytes,” Endocrinology, vol. 149, no. 10,
pp. 4970–4978, 2008.
[117] T. Doi, T. Sakoda,T. Akagamiet al., “Aldosterone induces in-
terleukin-18throughendothelin-1,angiotensinII,Rho/Rho-
kinase, and PPARs in cardiomyocytes,” American Journal of
Physiology, vol. 295, no. 3, pp. H1279–H1287, 2008.
[118] S. F. Mohammed, T. Ohtani, J. Korinek et al., “Mineralocor-
ticoid accelerates transition to heart failure with preserved
ejection fraction via “Nongenomic Eﬀects”,” Circulation,v o l .
122, pp. 370–378, 2010.
[119] S. Stas, A. Whaley-Connell, J. Habibi et al., “Mineralocor-
ticoid receptor blockade attenuates chronic overexpression
of the renin-angiotensin-aldosterone system stimulation of
reduced nicotinamide adenine dinucleotide phosphate oxi-
dase and cardiac remodeling,” Endocrinology, vol. 148, no. 8,
pp. 3773–3780, 2007.
[120] C. G. Brilla, L. S. Matsubara, and K. T. Weber, “Antiﬁbrotic
eﬀects of spironolactone in preventing myocardial ﬁbrosis
in systemic arterial hypertension,” American Journal of
Cardiology, vol. 71, no. 3, 1993.
[121] C. G. Brilla, G. Zhou, L. Matsubara, and K. T. Weber,
“Collagen metabolism in cultured adult rat cardiac ﬁbrob-
lasts: response to angiotensin II and aldosterone,” Journal ofInternational Journal of Hypertension 11
MolecularandCellular Cardiology,vol.26,no.7,pp.809–820,
1994.
[122] S. E. Campbell, J. S. Janicki, and K. T. Weber, “Temporal
diﬀerences in ﬁbroblast proliferation and phenotype expres-
sion in response to chronic administration of angiotensin II
or aldosterone,”Journal of Molecular and Cellular Cardiology,
vol. 27, no. 8, pp. 1545–1560, 1995.
[123] C. G. Brilla and K. T. Weber, “Mineralocorticoid excess,
dietary sodium, and myocardial ﬁbrosis,” Journal of Labora-
tory and Clinical Medicine,vol.120,no. 6,pp. 893–901,1992.
[124] R.Rocha,C.L.Martin-Berger,P.Yang,R.Scherrer,J.Delyani,
and E. McMahon, “Selective aldosterone blockade prevents
angiotensin II/salt-induced vascular inﬂammation in the rat
heart,” Endocrinology, vol. 143, no. 12, pp. 4828–4836, 2002.
[125] T. Y. Chun, L. J. Bloem, and J. H. Pratt, “Aldosterone inhibits
inducible nitric oxide synthase in neonatal rat cardiomy-
ocytes,” Endocrinology, vol. 144, no. 5, pp. 1712–1717, 2003.
[126] O. Pech´ aˇ nov´ a, I. Bern´ atov´ a, V. Pelouch, and P. Bab´ al, “L-
NAME-induced protein remodeling and ﬁbrosis in the rat
heart,” Physiological Research, vol. 48, no. 5, pp. 353–362,
1999.
[127] M. G. Ferrini, D. Vernet, T. R. Magee et al., “Antiﬁbrotic role
of inducible nitric oxide synthase,”Nitric Oxide,v o l .6 ,n o .3 ,
pp. 283–294, 2002.
[128] M. Carlstr¨ om, A. E. G. Persson, E. Larsson et al., “Dietary
nitrate attenuates oxidative stress, prevents cardiac and
renal injuries, and reduces blood pressure in salt-induced
hypertension,” Cardiovascular Research,v o l .8 9 ,n o .3 ,p p .
574–585, 2011.
[129] J. C. Hunter, A. Zeidan, S. Javadov, A. Kili´ c, V. Rajapurohi-
tam, and M. Karmazyn, “Nitric oxide inhibits endothelin-
1-induced neonatal cardiomyocyte hypertrophy via a RhoA-
ROCK-dependent pathway,” Journal of Molecular and Cellu-
lar Cardiology, vol. 47, no. 6, pp. 810–818, 2009.
[130] A. Gils and P. J. Declerck, “Plasminogen activator inhibitor-
1,” Current Medicinal Chemistry, vol. 11, pp. 2323–2334,
2004.
[131] I. Juhan-Vague and P. Vague, “Hypoﬁbrinolysis and insulin-
resistance,” Diabete et Metabolisme,v o l .1 7 ,n o .1 ,p a r t2 ,p p .
96–100, 1991.
[132] I. Mertens and L. F. van Gaal, “Obesity, haemostasis and the
ﬁbrinolyticsystem,”ObesityReviews,vol.3,no.2,pp.85–101,
2002.
[133] T. Skurk and H. Hauner, “Obesity and impaired ﬁbrinol-
ysis: role of adipose production of plasminogen activator
inhibitor-1,” International Journal of Obesity, vol. 28, no. 11,
pp. 1357–1364, 2004.
[134] J. B. Park and E. L. Schiﬀrin, “Cardiac and vascular
ﬁbrosis and hypertrophy in aldosterone-infused rats: role of
endothelin-1,” American Journal of Hypertension,v o l .1 5 ,n o .
2, pp. 164–169, 2002.
[135] Y. S. Lee, J. A. Kim, K. L. Kim et al., “Aldosterone
upregulates connective tissue growth factor gene expression
via p38 MAPK pathway and mineralocorticoid receptor in
ventricular myocytes,” Journal of Korean Medical Science,v o l .
19, no. 6, pp. 805–811, 2004.
[136] H. Matsui, K. Ando, H. Kawarazaki et al., “Salt excess causes
left ventricular diastolic dysfunction in rats with metabolic
disorder,” Hypertension, vol. 52, no. 2, pp. 287–294, 2008.
[137] J. Bauersachs and D. Fraccarollo, “Aldosterone antagonism
in addition to angiotensin-converting enzyme inhibitors in
heart failure,” Minerva Cardioangiologica, vol. 51, no. 2, pp.
155–164, 2003.
[138] C. W. Jewell, L. E. Watson,J. Mock,and D. E. Dostal, “Aldos-
teronereceptor antagonistsandcardiovasculardisease:dowe
need a change of the guard?” Cardiovascular and Hematolog-
ical Agents in Medicinal Chemistry, vol. 4, no. 2, pp. 129–153,
2006.
[139] B. Pitt, F. Zannad,W. J. Remme et al., “The eﬀect of spirono-
lactone on morbidity and mortality in patients with severe
heart failure,” The New England Journal of Medicine, vol.341,
no. 10, pp. 709–717, 1999.
[140] B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective
aldosteroneblocker, in patients with left ventricular dysfunc-
tion after myocardialinfarction,” The New England Journal of
Medicine, vol. 348, no. 14, pp. 1309–1321, 2003.
[141] C. G. Brilla, “Aldosterone and myocardial ﬁbrosis in heart
failure,” Herz, vol. 25, no. 3, pp. 299–306, 2000.
[142] M. Abuannadi andJ. H. O’Keefe, “Eplerenone: an underused
medication?” Journal of Cardiovascular Pharmacology and
Therapeutics, vol. 15, no. 4, pp. 318–325, 2010.
[143] Y. Sun, J. Zhang, L. Lu, S. S. Chen, M. T. Quinn, and K. T.
Weber, “Aldosterone-induced inﬂammation in the rat heart:
role of oxidative stress,” American Journal of Pathology,v o l .
161, no. 5, pp. 1773–1781, 2002.
[144] D. A. Siwik, P. J. Pagano, and W. S. Colucci, “Oxidative stress
regulates collagen synthesis and matrix metalloproteinase
activity in cardiac ﬁbroblasts,” American Journal of Physiol-
ogy, vol. 280, no. 1, pp. C53–C60, 2001.
[145] B. Huisamen, S. J.C. Pˆ e r e l ,S .O .F r i e d r i c h ,R .S a l i e ,H .S t r i -
jdom, and A. Lochner, “ANG II type i receptor antagonism
improved nitric oxide production and enhanced eNOS and
PKB/Akt expression in hearts from a rat model of insulin
resistance,” Molecular and Cellular Biochemistry, vol.349, no.
1-2, pp. 21–31, 2011.
[146] I. Tabbi-Anneni, J. Buchanan, R. C. Cooksey, and E. D.
Abel, “Captopril normalizes insulin signaling and insulin-
regulated substrate metabolism in obese (ob/ob) mouse
hearts,” Endocrinology, vol. 149, no. 8, pp. 4043–4050, 2008.
[147] A. M. Hilzendeger, A. C. Da Costa Goncalves, R. Plehm et
al., “Autonomic dysregulation in ob/ob mice is improved
by inhibition of angiotensin-converting enzyme,” Journal of
Molecular Medicine, vol. 88, no. 4, pp. 383–390, 2010.
[148] M. Fukuda, T. Nakamura, K. Kataoka et al., “Potentiation by
candesartan of protective eﬀects of pioglitazone against type
2 diabetic cardiovascular and renal complications in obese
mice,” Journal of Hypertension, vol. 28, no. 2, pp. 340–352,
2010.
[149] N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky,
“PPARα activators inhibit cytokine-induced vascular cell
adhesion molecule-1 expression in human endothelial cells,”
Circulation, vol. 99, no. 24, pp. 3125–3131, 1999.
[150] T. Kooistra, L. Verschuren, J. de Vries-van der Weij et al.,
“Fenoﬁbrate reduces atherogenesis in ApoE∗3Leiden mice:
evidenceformultipleantiatherogeniceﬀectsbesideslowering
plasma cholesterol,” Arteriosclerosis, Thrombosis, and Vascu-
lar Biology, vol. 26, no. 10, pp. 2322–2330, 2006.
[151] T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-
Tomobe,andI.Yamaguchi,“Myocardialﬁbrosisanddiastolic
dysfunction in deoxycorticosterone acetate-salt hypertensive
rats is ameliorated by the peroxisome proliferator-activated
receptor-alpha activator fenoﬁbrate, partly by suppressing
inﬂammatory responses associated with the nuclear factor-
kappa-B pathway,” Journal of the American College of Cardiol-
ogy, vol. 43, no. 8, pp. 1481–1488, 2004.12 International Journal of Hypertension
[152] T.-A. S. Duhaney, L. Cui, M. K. Rude et al., “Peroxisome
proliferator-activated receptor α-independent actions of fen-
oﬁbrate exacerbates left ventricular dilation and ﬁbrosis in
chronic pressure overload,” Hypertension,v o l .4 9 ,n o .5 ,p p .
1084–1094, 2007.
[153] N. K. LeBrasseur, T. A. S. Duhaney, D. S. De Silva et al.,
“Eﬀects of fenoﬁbrate on cardiac remodeling in aldosterone-
induced hypertension,” Hypertension, vol. 50, no. 3, pp. 489–
496, 2007.